BSE filing, NSE: INDRANIB. Summary written from the filing by ALFA Finder's alert engine.
Indrayani Biotech Ltd: key numbers
- Share price
- ₹8.22
- Market cap
- ₹44.11 Cr
- Revenue (annual)
- ₹137.8 Cr
- Net profit (annual)
- ₹2.16 Cr
- P/E (TTM)
- 21.0×Sector 26.2×
- Promoter holding
- 32.92%-0.34% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indrayani Biotech Ltd
All →Indrayani Biotech Legal & Regulatory
Indrayani Biotech received a tax recovery notice for outstanding demands totaling ₹1.17 Crore for various assessment years, for which the company has filed responses.
- Value
- ₹1.17 Cr
Indrayani Biotech Management Change
Independent Director Mr. K.S. Vaidyanathan has resigned from the Board of Indrayani Biotech Limited, effective October 13, 2026, due to personal reasons.
Indrayani Biotech Other Announcement
Indrayani Biotech Limited submitted the quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Indrayani Biotech Q1 FY27 Results: Net Profit ₹0.5 Cr, Up 150.0% YoY
Indrayani Biotech Ltd reported revenue from operations of ₹37.7 Cr (+29.6% YoY) and net profit of ₹0.5 Cr (+150.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.5 Cr · +150.0% YoY
Indrayani Biotech Board Meeting Date
Indrayani Biotech will hold a board meeting on October 7, 2026, to consider the company's unaudited financial results for the quarter ended June 30, 2026.
Indrayani Biotech Capital Structure Change
Indrayani Biotech announced its Rights Issue of up to 3.25 crore partly paid-up equity shares at ₹15 per share, aggregating to ₹48.79 Crore.
- Value
- ₹48.79 Cr
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr